Expression and clinical implication of Beclin1, HMGB1, p62, survivin, BRCA1 and ERCC1 in epithelial ovarian tumor tissues

European Review for Medical and Pharmacological Sciences

Volumn 20, Issue 10, 2016, Pages 1993-2003

  Ju, L L ^a   Zhao, C Y ^b   Ye, K F ^b   Yang, H ^b   Zhang, J ^b  

^a KUNMING UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b Pathology Department of First People's Hospital of Yunnan Province   (China)

Author keywords

Autophagy; Beclin1; BRCA1; Epithelial ovarian tumor tissues; ERCC1; HMGB1; p62; Platinum resistant.; Platinum sensitive; Survivin

Indexed keywords

BECLIN 1; BRCA1 PROTEIN; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; HIGH MOBILITY GROUP B1 PROTEIN; PLATINUM COMPLEX; PROTEIN P62; SURVIVIN;

ADULT; AGED; AUTOPHAGY; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER PATIENT; CANCER RESISTANCE; CANCER TISSUE; CHEMOSENSITIVITY; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; OVARY CARCINOMA; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REVIEW; TREATMENT RESPONSE; GENE EXPRESSION REGULATION; METABOLISM; OVARY TUMOR; PATHOPHYSIOLOGY;

BECLIN-1; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HMGB1 PROTEIN; HUMANS; OVARIAN NEOPLASMS;

EID: 84981721941     PISSN: 11283602     EISSN: 22840729     Source Type: Journal    
DOI: None     Document Type: Review

References (28)

1. WU WK, COFFELT SB, CHO CH, WANG XJ, LEE CW, CHAN FK, YU J, SUNG JJ. The autophagic paradox in cancer therapy. Oncogene 2012; 31: 939-953.
2. LIANG XH, KLEEMAN LK, JIANG HH, GORDON G, GOLDMAN JE, BERRY G, HERMAN B, LEVINE B. Protection against fatal Sindbis virus encephalitis by beclin, a novel Bcl-2-interacting protein. J Virol 1998; 72: 8586-8596.
3. YUE Z, JIN S, YANG C, LEVINE AJ, HEINTZ N. Beclin 1, an autophagy gene essential for early embryonic development, is a haploinsufficient tumor suppressor. Proc Natl Acad Sci U S A 2003; 100: 15077-15082.
4. ERLANDSSON HARRIS H, ANDERSSON U. Mini-review: The nuclear protein HMGB1 as a proinflammatory mediator. Eur J Immunol 2004; 34: 1503-1512.
5. CHEN J, XI B, ZHAO Y, YU Y, ZHANG J, WANG C. High-mobility group protein B1 (HMGB1) is a novel biomarker for human ovarian cancer. Gynecol Oncol 2012; 126: 109-117.
6. MATHEW R, KARP CM, BEAUDOIN B, VUONG N, CHEN G, CHEN HY, BRAY K, REDDY A, BHANOT G, GELINAS C, DIPAOLA RS, KARANTZA-WADSWORTH V, WHITE E. Autophagy suppresses tumorigenesis through elimination of p62. Cell 2009; 137: 1062-1075.
7. DEVERAUX QL, TAKAHASHI R, SALVESEN GS, REED JC. Xlinked IAP is a direct inhibitor of cell-death proteases. Nature 1997; 388: 300-304.
8. MAHOTKA C, WENZEL M, SPRINGER E, GABBERT HE, GERHARZ CD. Survivin-deltaEx3 and survivin-2B: Two novel splice variants of the apoptosis inhibitor survivin with different antiapoptotic properties. Can Res 1999; 59: 6097-6102
9. KANG CH, JANG BG, KIM DW, CHUNG DH, KIM YT, JHEON S, SUNG SW, KIM JH. The prognostic significance of ERCC1, BRCA1, XRCC1, and betaIIItubulin expression in patients with non-small cell lung cancer treated by platinum-And taxanebased neoadjuvant chemotherapy and surgical resection. Lung Can 2010; 68: 478-483
10. BHATTACHARYYA A, EAR US, KOLLER BH, WEICHSELBAUM RR, BISHOP DK. The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin. J Biol Chem 2000; 275: 23899-23903.
11. OZCAN MF, DIZDAR O, DINCER N, BALCI S, GULER G, GOK B, PEKTAS G, SEKER MM, AKSOY S, ARSLAN C, YALCIN S, BALBAY MD. Low ERCC1 expression is associated with prolonged survival in patients with bladder cancer receiving platinum-based neoadjuvant chemotherapy. Urol Oncol 2013; 31: 1709-1715.
12. DABHOLKAR M, BOSTICK-BRUTON F, WEBER C, BOHR VA, EGWUAGU C, REED E. ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients. J Natl Cancer Inst 1992; 84: 1512-1517.
13. MATHEW R, KARANTZA-WADSWORTH V, WHITE E. Role of autophagy in cancer. Nat Rev Cancer 2007; 7: 961-967.
14. DEGENHARDT K, MATHEW R, BEAUDOIN B, BRAY K, ANDERSON D, CHEN G, MUKHERJEE C, SHI Y, GELINAS C, FAN Y, NELSON DA, JIN S, WHITE E. Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and tumorigenesis. Can Cell 2006; 10: 51-64.
15. LIANG XH, JACKSON S, SEAMAN M, BROWN K, KEMPKES B, HIBSHOOSH H, LEVINE B. Induction of autophagy and inhibition of tumorigenesis by beclin 1. Nature 1999; 402: 672-676.
16. CAI M, HU Z, LIU J, GAO J, LIU C, LIU D, TAN M, ZHANG D, LIN B. Beclin 1 expression in ovarian tissues and its effects on ovarian cancer prognosis. Int J Mol Sci 2014; 15: 5292-5303.
17. DUAN ZL, PENG ZL, WANG ZH. Expression and involved signal transduction pathway of autophagy gene Beclin 1 in epithelial ovarian cancer. Sichuan da Xue Xue Bao Yi Xue Ban 2007; 38: 239-242.
18. SHEN Y, LI DD, WANG LL, DENG R, ZHU XF. Decreased expression of autophagy-related proteins in malignant epithelial ovarian cancer. Autophagy 2008; 4: 1067-1068.
19. CHEN Y, LU Y, LU C, ZHANG L. Beclin-1 expression is a predictor of clinical outcome in patients with esophageal squamous cell carcinoma and correlated to hypoxia-inducible factor (HIF)-1alpha expression. Pathol Oncol Res 2009; 15: 487-493.
20. PIRTOLI L, CEVENINI G, TINI P, VANNINI M, OLIVERI G, MARSILI S, MOURMOURAS V, RUBINO G, MIRACCO C. The prognostic role of Beclin 1 protein expression in high-grade gliomas. Autophagy 2009; 5: 930-936.
21. WAN XB, FAN XJ, CHEN MY, XIANG J, HUANG PY, GUO L, WU XY, XU J, LONG ZJ, ZHAO Y, ZHOU WH, MAI HQ, LIU Q, HONG MH. Elevated Beclin 1 expression is correlated with HIF-1alpha in predicting poor prognosis of nasopharyngeal carcinoma. Autophagy. 2010; 6: 395-404.
22. ZHANG Y, CHENG Y, REN X, ZHANG L, YAP KL, WU H, PATEL R, LIU D, QIN ZH, SHIH IM, YANG JM. NAC1 modulates sensitivity of ovarian cancer cells to cisplatin by altering the HMGB1-mediated autophagic response. Oncogene 2012; 31: 1055-1064.
23. MOSCAT J, DIAZ-MECO MT. p62 at the crossroads of autophagy, apoptosis, and cancer. Cell 2009; 137: 1001-1004.
24. COHEN C, LOHMANN CM, COTSONIS G, LAWSON D, SANTOIANNI R. Survivin expression in ovarian carcinoma: correlation with apoptotic markers and prognosis. Mod Pathol 2003; 16: 574-583
25. ZHANG HY, ZHANG PN, SUN H. Aberration of the PI3K/AKT/mTOR signaling in epithelial ovarian cancer and its implication in cisplatin-based chemotherapy. Eur J Obstet Gynecol Reprod Biol 2009; 146: 81-86.
26. SOBHIAN B, SHAO G, LILLI DR, CULHANE AC, MOREAU LA, XIA B, LIVINGSTON DM, GREENBERG RA. RAP80 targets BRCA1 to specific ubiquitin structures at DNA damage sites. Science 2007; 316: 1198-1202.
27. KARTALOU M, ESSIGMANN JM. Recognition of cisplatin adducts by cellular proteins. Mutat Res 2001; 478: 1-21
28. WANG L, WEI J, QIAN X, YIN H, ZHAO Y, YU L, WANG T, LIU B. ERCC1 and BRCA1 mRNA expression levels in metastatic malignant effusions is associated with chemosensitivity to cisplatin and/or docetaxel. BMC Cancer 2008; 8: 97.